SuperworthNatera, Inc. NTRA
Medical - Diagnostics & Research, Healthcare
$395.56
−1.27%
- Market cap
- $57B
- PE
- —
- Forward PE
- Price to sales
- 21.1×
- EV/EBIT
- —
- Revenue, 12 months
- $2.7B
- +38% on a year ago
- Net margin
- −7.1%
- Free cash flow yield
- 0.1%
Natera trades at 21.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.7B over the last twelve months, up 38% on a year earlier with a −7% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $311.1M | $367.7M | $413.4M | $439.8M | $476.1M+53% | $501.8M+37% | $546.6M+32% | $592.2M+35% | $665.5M+40% | $696.6M+39% | $752.8M+38% | |
| Cost of revenue | $151.2M | $159.1M | $170.2M | $168M | $176.4M+17% | $184.6M+16% | $199.5M+17% | $207.8M+24% | $218.7M+24% | $245.2M+33% | $267.6M+34% |
| Gross profit | $159.9M | $208.6M | $243.2M | $271.7M | $299.6M+87% | $317.2M+52% | $347.1M+43% | $384.4M+41% | $446.8M+49% | $451.4M+42% | $485.2M+40% |
| R&D | $83M | $88.6M | $89.1M | $96.9M | $129.5M+56% | $129.1M+46% | $146.4M+64% | $173.4M+79% | $175.2M+35% | $210.7M+63% | $228.1M+56% |
| SG&A | $161.4M | $194.3M | $198M | $214.2M | $234.9M+46% | $266.9M+37% | $310.5M+57% | $308.5M+44% | $291.3M+24% | $327.9M+23% | $327.2M+5% |
| −$84.5M | −$74.3M | −$43.9M | −$39.3M | −$64.7M−23% | −$79.2M+7% | −$110.4M+151% | −$97.6M+148% | −$22.8M−65% | −$93.5M+18% | −$75.8M−31% | |
| Interest expense | $3.1M | $3.1M | $3.1M | $3.1M | $1.3M−59% | $1M−68% | $1M−67% | $1M−67% | $7.1M+453% | $892K−11% | $890K−14% |
| Pre-tax income | −$77.8M | −$67.2M | −$36.6M | −$30.9M | −$55.1M−29% | −$66.8M−1% | −$100.7M+175% | −$87.3M+183% | −$13.3M−76% | −$84.8M+27% | −$67.2M−33% |
| $191K | $428K | $892K | $730K | −$1.4M | $173K−60% | $275K−69% | $207K−72% | −$60.6M+4371% | $283K+64% | −$261K | |
| Net income | −$78M | −$67.6M | −$37.5M | −$31.6M | −$53.8M−31% | −$66.9M−1% | −$100.9M+169% | −$87.5M+177% | $47.3M | −$85.1M+27% | −$67M−34% |
| −$0.65 | −$0.56 | −$0.30 | −$0.26 | −$0.41−37% | −$0.50−11% | −$0.74+147% | −$0.64+146% | $0.35 | −$0.60+20% | −$0.47−37% | |
| 119.3M | 120.8M | 122.9M | 123.8M | 124.7M+5% | 134.8M+12% | 136.4M+11% | 137.2M+11% | 136.7M+10% | 141.5M+5% | 143.3M+5% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Natera's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NTRANatera, Inc. | $57B | — | — | 21.1× | +38% | −7.1% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $244.8B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $41.5B | 35.1× | 33.9× | 6.3× | +8% | 15.5% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .